Melanoma, version 2.2016 clinical practice guidelines in oncology

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson, Gregory A. Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C. Fields, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. OlszanskiMerrick I. Ross, April K. Salama, Joseph Skitzki, Jeff Sosman, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, Anita Engh

Research output: Contribution to journalArticle

128 Scopus citations

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.

Original languageEnglish (US)
Pages (from-to)450-473
Number of pages24
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number4
DOIs
StatePublished - Apr 1 2016

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Coit, D. G., Thompson, J. A., Algazi, A., Andtbacka, R., Bichakjian, C. K., Carson, W. E., Daniels, G. A., DiMaio, D., Ernstoff, M., Fields, R. C., Fleming, M. D., Gonzalez, R., Guild, V., Halpern, A. C., Hodi, F. S., Joseph, R. W., Lange, J. R., Martini, M. C., Materin, M. A., ... Engh, A. (2016). Melanoma, version 2.2016 clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 14(4), 450-473. https://doi.org/10.6004/jnccn.2016.0051